{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:39:43Z","timestamp":1795034383505,"version":"4.10.2"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.neurobiolaging.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T20:43:53Z","timestamp":1647981833000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-6362","authenticated-orcid":false,"given":"Yonghe","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse R.","family":"Macyczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119310","article-title":"HMGB1\/RAGE\/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis","volume":"273","author":"Abuelezz","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0002","doi-asserted-by":"crossref","first-page":"628 e1","DOI":"10.1016\/j.neurobiolaging.2011.04.010","article-title":"Association of ApoE and LRP mRNA levels with dementia and AD neuropathology","volume":"33","author":"Akram","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0003","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0004","doi-asserted-by":"crossref","first-page":"13707","DOI":"10.1523\/JNEUROSCI.4040-10.2010","article-title":"Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice","volume":"30","author":"Andrews-Zwilling","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010838","article-title":"Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation","volume":"8","author":"Apaijai","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0006","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0007","doi-asserted-by":"crossref","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","article-title":"Apolipoprotein E Is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2)","volume":"290","author":"Atagi","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0008","doi-asserted-by":"crossref","first-page":"26033","DOI":"10.1074\/jbc.M115.677286","article-title":"The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E","volume":"290","author":"Bailey","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0009","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0010","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","article-title":"Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease","volume":"96","author":"Bales","year":"1999","journal-title":"P Natl AcadSci USA"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0011","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1197-263","article-title":"Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition","volume":"17","author":"Bales","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A","volume":"485","author":"Bell","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0013","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A Quarter century of APOE and Alzheimer's disease: progress to date and the path forward","volume":"101","author":"Belloy","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0014","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu Rev Pharmacol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0015","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1073\/pnas.1710329115","article-title":"Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer\u2019s disease","volume":"115","author":"Bennett","year":"2018","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng1934","article-title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database","volume":"39","author":"Bertram","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0169-328X(95)00097-C","article-title":"Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease","volume":"33","author":"Bertrand","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0018","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1523\/JNEUROSCI.0033-12.2012","article-title":"Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice","volume":"32","author":"Bien-Ly","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0019","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3233\/JAD-160467","article-title":"ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies","volume":"54","author":"Boehm-Cagan","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0020","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.neurobiolaging.2005.09.011","article-title":"Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice","volume":"27","author":"Cao","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0021","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.1206446109","article-title":"Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis","volume":"109","author":"Castellano","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0022","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1073\/pnas.0914984107","article-title":"ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling","volume":"107","author":"Chen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad1904","article-title":"The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis","volume":"7","author":"Choi","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0024","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0026","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0027","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer\u2019s disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0029","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1750-3639.1998.tb00166.x","article-title":"Microglial activation in Alzheimer disease: association with APOE genotype","volume":"8","author":"Egensperger","year":"1998","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0030","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"Jama"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0032","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3233\/JAD-190914","article-title":"Carnosic acid reverses the inhibition of ApoE4 on cell surface level of ApoER2 and reelin signaling pathway","volume":"73","author":"Feng","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0033","series-title":"Doctoral Dissertation: Modulating ApoE with Tissue Specific siRNAs in Alzheimer\u2019s Disease. Morningside Graduate School of Biomedical Sciences Dissertations and Theses","author":"Ferguson","year":"2021"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0034","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer's disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0035","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuroimage.2008.10.003","article-title":"Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease","volume":"44","author":"Filippini","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104724","article-title":"APOE in the normal brain","volume":"136","author":"Flowers","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0037","doi-asserted-by":"crossref","first-page":"25754","DOI":"10.1074\/jbc.M502143200","article-title":"The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice","volume":"280","author":"Fryer","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00490-z","article-title":"Talking points for physicians, patients and caregivers considering Aduhelm(R) infusion and the accelerated pathway for its approval by the FDA","volume":"16","author":"Gandy","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00518-19","article-title":"Therapeutic IDOL reduction ameliorates amyloidosis and improves cognitive function in APP\/PS1 mice","volume":"40","author":"Gao","year":"2020","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29178","article-title":"The E3 ubiquitin ligase IDOL regulates synaptic ApoER2 levels and is important for plasticity and learning","volume":"6","author":"Gao","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0041","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0042","doi-asserted-by":"crossref","first-page":"29919","DOI":"10.1074\/jbc.M203934200","article-title":"Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice","volume":"277","author":"Gong","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0043","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0045","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0046","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8","article-title":"Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model","volume":"47","author":"Holtzman","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0047","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0048","doi-asserted-by":"crossref","first-page":"19720","DOI":"10.1074\/jbc.M110.123729","article-title":"The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2","volume":"285","author":"Hong","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0049","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cmet.2014.10.001","article-title":"The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice","volume":"20","author":"Hong","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-015-0001-3","article-title":"Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice","volume":"10","author":"Hu","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0051","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","article-title":"Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis","volume":"96","author":"Huynh","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-0835-4","article-title":"The Alzheimer\u2019s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway","volume":"14","author":"Jendresen","year":"2017","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0053","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0054","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting development of Alzheimer\u2019s disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0031","unstructured":"FDA. 2021. Drugs@FDA: FDA-approved drugs. Accessed from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=214012."},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0055","unstructured":"Khvorova A, Ferguson F, Rogaev E. 2020. Oligonucleotides for tissue specific apoe modulation. Accessed from: https:\/\/patents.justia.com\/patent\/20200362341."},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0056","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","article-title":"Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance","volume":"64","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0057","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A beta amyloidosis","volume":"209","author":"Kim","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0058","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1523\/JNEUROSCI.3773-11.2011","article-title":"Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis","volume":"31","author":"Kim","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00754","article-title":"The Important Interface between apolipoprotein E and neuroinflammation in Alzheimer\u2019s disease","volume":"11","author":"Kloske","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0060","doi-asserted-by":"crossref","first-page":"e3331","DOI":"10.1212\/WNL.0000000000010852","article-title":"Association of common genetic variants with brain microbleeds: a genome-wide association study","volume":"95","author":"Knol","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0061","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.05.007","article-title":"ATP-binding cassette transporter A1: from metabolism to neurodegeneration","volume":"72","author":"Koldamova","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0062","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-pathmechdis-030421-112756","article-title":"Apolipoprotein E and Alzheimer\u2019s disease: findings, hypotheses, and potential mechanisms","volume":"17","author":"Koutsodendris","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0063","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0064","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1021\/acschembio.0c00851","article-title":"Small molecule phenotypic screen identifies novel regulators of LDLR expression","volume":"15","author":"Krishnan","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1194\/jlr.R075507","article-title":"The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease","volume":"58","author":"Lane-Donovan","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176336","article-title":"ApoE Lipidation as a therapeutic target in Alzheimer\u2019s disease","volume":"21","author":"Lanfranco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0067","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aba4624","article-title":"Antisense oligonucleotides for neurodegeneration","volume":"367","author":"Leavitt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0068","article-title":"Redefining transcriptional regulation of the APOE gene and its association with Alzheimer's disease","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0069","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s42255-019-0127-7","article-title":"IDOL regulates systemic energy balance through control of neuronal VLDLR expression","volume":"1","author":"Lee","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0070","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.neuron.2021.01.005","article-title":"Astrocytic ApoE reprograms neuronal cholesterol metabolism and histone-acetylation-mediated memory","volume":"109","author":"Li","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0071","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-020-00413-4","article-title":"APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease","volume":"15","author":"Li","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0072","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1471-4159.2004.02183.x","article-title":"A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes","volume":"88","author":"Liang","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0073","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE antibody given after plaque onset decreases a beta accumulation and improves brain function in a mouse model of a beta amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0074","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0076","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ana.26043","article-title":"Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model","volume":"89","author":"Litvinchuk","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0077","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0078","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2007.08.008","article-title":"Amyloid precursor protein regulates brain apolipoprotein e and cholesterol metabolism through lipoprotein receptor LRP1","volume":"56","author":"Liu","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0079","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205013666160404120817","article-title":"An Anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 In Vivo","volume":"13","author":"Luz","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/372092a0","article-title":"Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments","volume":"372","author":"Ma","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0081","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00436-5","article-title":"TREM2\/PLCgamma2 signalling in immune cells: function, structural insight, and potential therapeutic modulation","volume":"16","author":"Magno","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0082","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaneurol.2014.2011","article-title":"Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function","volume":"71","author":"Mak","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0083","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.15252\/embr.201439225","article-title":"Cholesterol in brain disease: sometimes determinant and frequently implicated","volume":"15","author":"Martin","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0084","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","article-title":"Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls","volume":"127","author":"Martinez-Morillo","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","article-title":"Single-cell transcriptomic analysis of Alzheimer's disease","volume":"570","author":"Mathys","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0086","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0087","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00467-y","article-title":"The informed road map to prevention of Alzheimer disease: a call to arms","volume":"16","author":"McDade","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0088","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/brain\/awy103","article-title":"Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE epsilon4 genotype","volume":"141","author":"Mishra","year":"2018","journal-title":"Brain"},{"issue":"70","key":"10.1016\/j.neurobiolaging.2022.03.011_bib0089","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0090","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1084\/jem.20171406","article-title":"Alzheimer's disease: A matter of blood-brain barrier dysfunction?","volume":"214","author":"Montagne","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0091","article-title":"Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer\u2019s disease-associated genes","volume":"28","author":"Moulton","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0092","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154889","article-title":"Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside","volume":"131","author":"Musiek","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0093","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0094","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00502-y","article-title":"Basal lamina changes in neurodegenerative disorders","volume":"16","author":"Nguyen","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fnins.2020.00609","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders","volume":"14","author":"O'Connell","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0096","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/gps.2344","article-title":"APOE epsilon-4 allele and cytokine production in Alzheimer's disease","volume":"25","author":"Olgiati","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0097","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","article-title":"Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE","volume":"22","author":"Parhizkar","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0098","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220254","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer's disease: a genetic and proteomic multi-cohort study","volume":"14","author":"Picard","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0099","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(96)00183-7","article-title":"Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls","volume":"722","author":"Pirttila","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0100","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0101","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","article-title":"Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein","volume":"333","author":"Polvikoski","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0102","first-page":"2083","article-title":"Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease","volume":"148","author":"Premkumar","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0103","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","article-title":"LRP1 is a master regulator of tau uptake and spread","volume":"580","author":"Rauch","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0104","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"P Natl Acad Sci USA"},{"issue":"23","key":"10.1016\/j.neurobiolaging.2022.03.011_bib0105","article-title":"Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E","volume":"15","author":"Robert","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0106","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-11-111","article-title":"Human APOE4 increases microglia reactivity at A beta plaques in a mouse model of A beta deposition","volume":"11","author":"Rodriguez","year":"2014","journal-title":"J Neuroinflamm"},{"issue":"64","key":"10.1016\/j.neurobiolaging.2022.03.011_bib0107","article-title":"ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0109","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.90.20.9649","article-title":"Increased amyloid beta-peptide deposition in cerebral-cortex as a consequence of apolipoprotein-e genotype in late-onset Alzheimer-disease","volume":"90","author":"Schmechel","year":"1993","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1533317513505133","article-title":"Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease","volume":"29","author":"Schmidt","year":"2014","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0111","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1532-5415.2007.01159.x","article-title":"Systemic markers of inflammation and cognitive decline in old age","volume":"55","author":"Schram","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0112","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.neuron.2021.05.034","article-title":"Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms","volume":"109","author":"Shi","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0113","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","article-title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight","volume":"18","author":"Shi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","article-title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight","volume":"18","author":"Shi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0116","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0117","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s11064-008-9588-x","article-title":"Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals","volume":"33","author":"Sihlbom","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41593-020-0599-5","article-title":"The multiplex model of the genetics of Alzheimer's disease","volume":"23","author":"Sims","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107843","article-title":"Alzheimer\u2019s patient microglia exhibit enhanced aging and unique transcriptional activation","volume":"31","author":"Srinivasan","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jns.2015.12.004","article-title":"Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"360","author":"Talwar","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0121","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","article-title":"Association of apolipoprotein E epsilon4 with medial temporal tau independent of amyloid-beta","volume":"77","author":"Therriault","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0122","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-013-1236-0","article-title":"CSF Apo-E levels associate with cognitive decline and MRI changes","volume":"127","author":"Toledo","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0123","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.20171265","article-title":"ApoE facilitates the microglial response to amyloid plaque pathology","volume":"215","author":"Ulrich","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0124","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/glia.24078","article-title":"Exploring reported genes of microglia RNA-sequencing data: Uses and considerations","volume":"69","author":"van Wageningen","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/01.wnl.0000307750.41970.d9","article-title":"Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study","volume":"70","author":"Vernooij","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0126","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","article-title":"Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0127","doi-asserted-by":"crossref","first-page":"1657-74","DOI":"10.1016\/j.neuron.2021.03.024","article-title":"Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia","volume":"109","author":"Wang","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0128","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab126","article-title":"Interactive rather than independent effect of APOE and sex potentiates tau deposition in women","volume":"3","author":"Wang","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/alz.12173","article-title":"APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia","volume":"17","author":"Weigand","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.03.011_bib0130","article-title":"Therapeutic approaches targeting Apolipoprotein E function in Alzheimer\u2019s disease","volume":"15","author":"Williams","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0131","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40048","article-title":"Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer\u2019s disease","volume":"7","author":"Xian","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0132","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0133","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuron.2020.11.019","article-title":"Vascular ApoE4 impairs behavior by modulating gliovascular function","volume":"109","author":"Yamazaki","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0134","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fncel.2019.00457","article-title":"Distinct signaling pathways regulate TREM2 phagocytic and NFkappaB antagonistic activities","volume":"13","author":"Yao","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0136","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","article-title":"TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia","volume":"91","author":"Yeh","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0137","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s42003-021-02841-4","article-title":"Astrocytic ApoE underlies maturation of hippocampal neurons and cognitive recovery after traumatic brain injury in mice","volume":"4","author":"Yu","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0138","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor","volume":"325","author":"Zelcer","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0139","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1073\/pnas.0305803101","article-title":"Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein","volume":"101","author":"Zerbinatti","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0140","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1101\/gad.2056211","article-title":"The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor","volume":"25","author":"Zhang","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0142","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1038\/s41467-020-19264-0","article-title":"APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0143","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","article-title":"Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease","volume":"26","author":"Zhou","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0144","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/glia.22289","article-title":"APOE genotype alters glial activation and loss of synaptic markers in mice","volume":"60","author":"Zhu","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2022.03.011_bib0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-160411","article-title":"Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer's disease","volume":"55","author":"Zimetti","year":"2017","journal-title":"J Alzheimers Dis"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458022000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458022000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:41:54Z","timestamp":1759318914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458022000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":145,"alternative-id":["S0197458022000550"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.03.011","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}